about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosisChanges in the incidence of candidiasis in neonatal intensive care units.Safety and pharmacokinetics of repeat-dose micafungin in young infants.Pharmacokinetics of an elevated dosage of micafungin in premature neonates.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Population pharmacokinetics of micafungin in neonates and young infantsPharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosisPulmonary penetration of piperacillin and tazobactam in critically ill patients.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.Population pharmacokinetics of teicoplanin in children.Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis.Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapyFluconazole loading dose pharmacokinetics and safety in infantsSafety and pharmacokinetics of multiple-dose anidulafungin in infants and neonatesComparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patientsPopulation pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectGene expression profiles of human dendritic cells interacting with Aspergillus fumigatus in a bilayer model of the alveolar epithelium/endothelium interfaceObservational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsPharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Achieving target voriconazole concentrations more accurately in children and adolescents.Population pharmacokinetics of voriconazole in adultsAnidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosingPopulation Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infectionsPharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.
P50
Q26771848-7AC4D169-C391-4615-9543-204E197F0BFDQ26771850-FC5C055C-0C6C-49F7-B137-1B7044B9385AQ28080607-7DDB9DC0-138C-42E1-A916-1AE8A1421C66Q28727508-4B065AAE-66F0-4FAC-8A03-E0B9B961B53CQ30408409-89B613E9-7FB1-4A73-A73C-C5BF67F0197CQ30433612-A39827C4-F250-4864-BA15-E53211F696C7Q30436332-E6A024A1-D61E-4890-84D2-390A882E5141Q30844731-A9F586A3-84F9-487B-8FC5-A471F2806045Q33696043-F0A0E1C3-942E-4652-B2E3-9161A5026272Q33726698-9D39EB7B-273A-4DFA-AD9B-F59F3A642ED5Q33798203-7361F274-BC6B-41B0-A014-656714CE457CQ33876608-6FA4682D-BE71-4307-AE05-E234B55A2FF5Q34045435-C918E4FF-BFE0-45A6-8920-CA39B611F024Q34216623-4FCD2889-11DB-48C2-819E-28B2D521E7C8Q34274190-7DA541FB-35AD-44C6-8254-06E21034637DQ34290097-719EE4B1-90E5-4D8F-8299-911E4DF48455Q34427584-C4D62508-8548-4303-B6DD-E40D5A339DDCQ34596321-40700F65-4886-4FDA-97C2-54D738C52CF6Q34719835-D0CAC133-C55E-4A38-8DF8-B1CC6F91ED28Q34754956-9E90CB52-8CBB-4B58-B20E-C85CF29A58DAQ34807770-75D679C6-85D8-4D88-82D8-E649D29A2217Q35071572-14937115-EBF0-4F00-9A06-0EEE6457AF9FQ35076958-DF5B82E2-E516-41AE-95E5-77BBE77E218FQ35105985-E35AC7B0-1DA3-495F-8E3C-DA517E4C5FBEQ35127913-8E8F0067-8D2E-4EEE-8B39-95CACEA09215Q35175339-28467C33-D138-486B-A5B8-F2A914AA401BQ35270270-6C3467D4-BDF7-464F-8155-AF3DA5385F7AQ35270758-7516EC62-0146-4FC2-9DB5-448E1C5903CCQ35385786-0951EFB6-3AF5-4A56-B766-623E472AE5C3Q35607652-A9B21D61-E373-43D6-BB70-316D94155E58Q35666490-EA6703E9-B7FD-4566-8CE2-63EF74E12E1BQ35689202-BCF2C03B-179E-42B5-A252-57907347B6F3Q35776693-F50F2F9A-4072-4E78-9192-DA81B2DCD2E3Q35941237-01FD9877-9752-41DC-A694-E34CEC263B66Q35960788-F77A6823-88C2-4B47-A8A7-FE57206F0BFEQ36094957-38C35B78-5AC1-4DE2-A513-C1887A51F50EQ36094962-C0653479-2FB7-4AC7-B261-F10AD199EF77Q36099895-E72C0A09-B570-49B5-9854-8639B3214FFBQ36171570-50F20BCC-C7CB-4842-9865-228900175E41Q36171643-48AA22A0-4BC7-47B1-80B8-362270D32C89
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
William Hope
@ast
William Hope
@en
William Hope
@es
William Hope
@nl
William Hope
@sl
type
label
William Hope
@ast
William Hope
@en
William Hope
@es
William Hope
@nl
William Hope
@sl
prefLabel
William Hope
@ast
William Hope
@en
William Hope
@es
William Hope
@nl
William Hope
@sl
P106
P1153
35344753400
P21
P31
P3835
william-hope1
P496
0000-0001-6187-878X